Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh V. Ph D. Patel sold 12,859 shares of the business's stock in a transaction on Monday, July 21st. The stock was sold at an average price of $54.86, for a total value of $705,444.74. Following the completion of the sale, the chief executive officer directly owned 570,603 shares in the company, valued at $31,303,280.58. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Protagonist Therapeutics Price Performance
Shares of NASDAQ:PTGX traded up $1.41 during midday trading on Friday, hitting $55.15. The company had a trading volume of 490,995 shares, compared to its average volume of 973,621. The company has a market cap of $3.42 billion, a price-to-earnings ratio of 73.53 and a beta of 2.26. Protagonist Therapeutics, Inc. has a 12-month low of $32.50 and a 12-month high of $60.60. The company has a fifty day moving average of $52.09 and a two-hundred day moving average of $46.03.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 9.22% and a net margin of 27.04%. The firm had revenue of $28.32 million during the quarter, compared to analyst estimates of $30.44 million. Research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have commented on PTGX. Citigroup began coverage on Protagonist Therapeutics in a report on Tuesday, June 17th. They issued a "buy" rating and a $72.00 target price for the company. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, June 3rd. Wall Street Zen raised Protagonist Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 8th. Finally, Wedbush restated an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a research note on Friday, March 28th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Protagonist Therapeutics has an average rating of "Moderate Buy" and an average target price of $66.10.
View Our Latest Research Report on PTGX
Hedge Funds Weigh In On Protagonist Therapeutics
Institutional investors have recently bought and sold shares of the stock. Deep Track Capital LP purchased a new stake in Protagonist Therapeutics during the fourth quarter valued at $38,600,000. Wellington Management Group LLP lifted its position in shares of Protagonist Therapeutics by 3,025.4% during the fourth quarter. Wellington Management Group LLP now owns 940,077 shares of the company's stock worth $36,287,000 after purchasing an additional 909,998 shares during the last quarter. BVF Inc. IL boosted its stake in shares of Protagonist Therapeutics by 35.5% during the first quarter. BVF Inc. IL now owns 2,575,015 shares of the company's stock valued at $124,528,000 after purchasing an additional 675,000 shares during the period. American Century Companies Inc. boosted its stake in shares of Protagonist Therapeutics by 61.5% during the fourth quarter. American Century Companies Inc. now owns 928,286 shares of the company's stock valued at $35,832,000 after purchasing an additional 353,511 shares during the period. Finally, New Vernon Capital Holdings II LLC increased its stake in Protagonist Therapeutics by 11,271.9% in the 1st quarter. New Vernon Capital Holdings II LLC now owns 348,095 shares of the company's stock worth $16,834,000 after buying an additional 345,034 shares during the period. 98.63% of the stock is owned by hedge funds and other institutional investors.
About Protagonist Therapeutics
(
Get Free Report)
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Further Reading
Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
